An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Sep 2014
At a glance
- Drugs Carotuximab (Primary) ; Bevacizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors TRACON Pharmaceuticals
- 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 May 2013 Results will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).